SQZ BIOTECHNOLOGIES CO (SQZ) Fundamental Analysis & Valuation

NYSE:SQZ • US78472W1045

Current stock price

0.435 USD
+0.16 (+61.11%)
At close:
0.4384 USD
+0 (+0.78%)
After Hours:

This SQZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SQZ Profitability Analysis

1.1 Basic Checks

  • SQZ had negative earnings in the past year.
  • SQZ had a negative operating cash flow in the past year.
SQZ Yearly Net Income VS EBIT VS OCF VS FCFSQZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

  • The profitability ratios for SQZ are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SQZ Yearly ROA, ROE, ROICSQZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

  • SQZ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SQZ Yearly Profit, Operating, Gross MarginsSQZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SQZ Health Analysis

2.1 Basic Checks

  • SQZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SQZ has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for SQZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SQZ Yearly Shares OutstandingSQZ Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
SQZ Yearly Total Debt VS Total AssetsSQZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -7.89, we must say that SQZ is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -7.89, SQZ is not doing good in the industry: 73.06% of the companies in the same industry are doing better.
  • SQZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.89
ROIC/WACCN/A
WACC8.56%
SQZ Yearly LT Debt VS Equity VS FCFSQZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 3.50 indicates that SQZ has no problem at all paying its short term obligations.
  • SQZ's Current ratio of 3.50 is on the low side compared to the rest of the industry. SQZ is outperformed by 63.71% of its industry peers.
  • A Quick Ratio of 3.50 indicates that SQZ has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.50, SQZ is not doing good in the industry: 62.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.5
SQZ Yearly Current Assets VS Current LiabilitesSQZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SQZ Growth Analysis

3.1 Past

  • SQZ shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.89%.
  • SQZ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.08%.
  • Measured over the past years, SQZ shows a small growth in Revenue. The Revenue has been growing by 2.22% on average per year.
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-24.08%
Revenue growth 3Y2.22%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • SQZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 60.76% yearly.
  • The Revenue is expected to grow by 155.08% on average over the next years. This is a very strong growth
EPS Next Y19.72%
EPS Next 2Y32.19%
EPS Next 3Y20.67%
EPS Next 5Y60.76%
Revenue Next Year65.7%
Revenue Next 2Y134.76%
Revenue Next 3Y108.16%
Revenue Next 5Y155.08%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SQZ Yearly Revenue VS EstimatesSQZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
SQZ Yearly EPS VS EstimatesSQZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

1

4. SQZ Valuation Analysis

4.1 Price/Earnings Ratio

  • SQZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SQZ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SQZ Price Earnings VS Forward Price EarningsSQZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SQZ Per share dataSQZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SQZ's earnings are expected to grow with 20.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.19%
EPS Next 3Y20.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SQZ Dividend Analysis

5.1 Amount

  • SQZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SQZ Fundamentals: All Metrics, Ratios and Statistics

SQZ BIOTECHNOLOGIES CO

NYSE:SQZ (7/3/2023, 8:01:56 PM)

After market: 0.4384 +0 (+0.78%)

0.435

+0.16 (+61.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10
Earnings (Next)08-02
Inst Owners0.01%
Inst Owner Change0%
Ins Owners10.69%
Ins Owner Change0%
Market Cap12.83M
Revenue(TTM)18.61M
Net Income(TTM)-76.11M
Analysts76.67
Price Target19.38 (4355.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.49%
Min EPS beat(2)-10.01%
Max EPS beat(2)62.99%
EPS beat(4)3
Avg EPS beat(4)15.45%
Min EPS beat(4)-10.01%
Max EPS beat(4)62.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.37%
Min Revenue beat(2)-100%
Max Revenue beat(2)130.74%
Revenue beat(4)1
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-100%
Max Revenue beat(4)130.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.45%
EPS NY rev (1m)0%
EPS NY rev (3m)6.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-46.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)33.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.69
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-2.45
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-2.96
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0.63
BVpS1.36
TBVpS1.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.5
Quick Ratio 3.5
Altman-Z -7.89
F-Score2
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)57.84%
Cap/Depr(5y)90.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y19.72%
EPS Next 2Y32.19%
EPS Next 3Y20.67%
EPS Next 5Y60.76%
Revenue 1Y (TTM)-24.08%
Revenue growth 3Y2.22%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year65.7%
Revenue Next 2Y134.76%
Revenue Next 3Y108.16%
Revenue Next 5Y155.08%
EBIT growth 1Y1.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year229.46%
EBIT Next 3Y53.65%
EBIT Next 5YN/A
FCF growth 1Y-1.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.72%
OCF growth 3YN/A
OCF growth 5YN/A

SQZ BIOTECHNOLOGIES CO / SQZ Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SQZ BIOTECHNOLOGIES CO?

ChartMill assigns a fundamental rating of 3 / 10 to SQZ.


Can you provide the valuation status for SQZ BIOTECHNOLOGIES CO?

ChartMill assigns a valuation rating of 1 / 10 to SQZ BIOTECHNOLOGIES CO (SQZ). This can be considered as Overvalued.


How profitable is SQZ BIOTECHNOLOGIES CO (SQZ) stock?

SQZ BIOTECHNOLOGIES CO (SQZ) has a profitability rating of 0 / 10.


What is the expected EPS growth for SQZ BIOTECHNOLOGIES CO (SQZ) stock?

The Earnings per Share (EPS) of SQZ BIOTECHNOLOGIES CO (SQZ) is expected to grow by 19.72% in the next year.